date,title,source
Oct-17-18,Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinsons Disease at 2018 American Neurological Association Annual Meeting,GlobeNewswire
Oct-23-18,Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinsons Disease,GlobeNewswire
Oct-25-18,"Investor Expectations to Drive Momentum within Tribune Media, Intra-Cellular Therapies, Icahn Enterprises, NVE, PetMed Express, and United Fire Group  Discovering Underlying Factors of Influence",GlobeNewswire
